Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 and up

Supplemental vitamin A and nicotinamide for kidney transplant recipients at high risk of skin cancer

Official title: Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide

Run by Rhode Island Hospital · NCT05702398 · Data updated 2026-11-12

This pilot will test whether taking oral nicotinamide and vitamin A is safe and doable for kidney transplant recipients who have had recent skin cancers.

More Skin Cancer trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorRhode Island Hospital
Academic / other
Locations1 site (Providence, Rhode Island)
StatusRecruiting
StartedApril 1, 2023
Main results expectedJanuary 1, 2028
Study endsMarch 1, 2028
Registry record updatedMarch 20, 2026
Trial IDNCT05702398 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who have received a kidney transplant and have a recent history of multiple invasive cutaneous squamous cell carcinomas or extensive treated premalignant skin lesions are the intended participants.

Probably not a fit

People with active liver disease, recent myocardial infarction, eGFR <15 mL/min/1.73 m2, pregnancy or lactation, genetic skin cancer syndromes, very large numbers of current skin cancers, metastatic SCC or recent invasive melanoma, or those taking interacting drugs like carbamazepine are not likely to be eligible or benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase pilot enrolls adult kidney transplant recipients with a recent history of multiple cutaneous squamous cell carcinomas or extensive treated premalignant lesions. Participants will take oral nicotinamide and vitamin A or a matching placebo while investigators monitor safety, tolerability, and adherence. The trial excludes people with significant liver disease, recent myocardial infarction, certain medication interactions, very low kidney function, pregnancy, or genetic skin cancer syndromes. Findings will provide preliminary safety and feasibility data to guide larger cancer prevention trials in this high-risk population.

Why it matters

Potential benefit: If successful, the regimen could reduce future skin cancers in transplant recipients and support larger prevention trials.

How similar studies have gone: Oral nicotinamide has reduced new nonmelanoma skin cancers in other high-risk groups, but the combination with vitamin A in kidney transplant recipients is less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years old or greater;
* Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or
* At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);
* Understands, reads, and writes English proficiently.

Exclusion Criteria:

* Liver disease;
* Active peptic ulcer disease;
* Recent myocardial infarction;
* Hypotension;
* Internal malignancy within past 5 years;
* Renal impairment with eGFR\<15 mL/min/1.73 m2;
* Being unable for follow up due to social reasons;
* Gorlin's syndrome or other genetic skin cancer syndrome;
* Huge number of current skin cancers;
* Metastatic SCC or invasive melanoma within the past 5 years;
* Pregnancy or lactation;
* Need for ongoing carbamazepine use (which could have a possible interaction with NAM);
* Use of acitretin or other oral retinoids within the past 6 months;
* Use of supplemental NAM, niacin, vitamin A, or beta carotene within the past 6 months;
* Field treatment for actinic keratoses (AKs) within the previous 4 weeks;
* Use of topical steroids.

Where it's running

  • Rhode Island Hospital
    Providence, Rhode Island, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.